--- title: "16:01 ETKalohexis Announces Poster Presentation at the American Association for Cancer Research Annual Meeting 2026" type: "News" locale: "en" url: "https://longbridge.com/en/news/283188827.md" description: "Kalohexis, a clinical-stage biotechnology company, announced a poster presentation at the AACR Annual Meeting 2026, scheduled for April 17-22 in San Diego, CA. The presentation will detail the ongoing Phase 2 Paradox trial evaluating mifomelatide for cachexia in advanced colorectal cancer patients. Key endpoints include changes in body weight and quality of life. The poster presentation is set for April 21, 2026, from 9:00 a.m. to 12:00 p.m. PT, focusing on Phase II and III clinical trials in progress." datetime: "2026-04-17T20:02:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283188827.md) - [en](https://longbridge.com/en/news/283188827.md) - [zh-HK](https://longbridge.com/zh-HK/news/283188827.md) generator: "portal-rs" --- # 16:01 ETKalohexis Announces Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 , /PRNewswire/ -- Kalohexis, a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, today announced a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, CA. At AACR 2026, a trials-in-progress poster will be presented by Endevica Bio highlighting the study design of the ongoing Phase 2 Paradox trial (NCT06937177) to evaluate the safety, tolerability and efficacy of mifomelatide for cachexia in patients with advanced colorectal cancer. The trial was initiated in Q2 2025 by Endevica Bio and is currently being administered by Kalohexis. Primary endpoints include change from baseline in body weight, incidence and severity of AEs, and incidence of lab or vital sign abnormalities; secondary endpoints include change from baseline in appetite and quality of life. **Poster Presentation Details:** **Title:** A randomized, double-blind, placebo-controlled Phase 2 study of mifomelatide (TCMCB07) in patients with newly diagnosed metastatic colorectal cancer undergoing chemotherapy: The Paradox Trial **Presentation Number:** CT219 **Date and Time:** April 21, 2026, 9:00 a.m. – 12:00 p.m. PT **Session:** Phase II and Phase III Clinical Trials in Progress **Location:** Poster Section 51; Poster Board #14 **About** **Kalohexis** Kalohexis is a clinical-stage biotechnology company shaping the next era of metabolic disease care by harnessing the melanocortin (MC) system, the body's natural regulator of metabolic homeostasis, to help people live healthier lives. Kalohexis' first- and best-in-class therapeutic peptides are designed to safely and effectively drug central melanocortin-3 and -4 receptors (MC3R/MC4R) to treat many metabolic disorders. Kalohexis' lead pipeline programs are 710GO, an oral dual MC3R/MC4R agonist to induce healthier, more durable weight loss in general obesity, and mifomelatide, a dual MC3R/MC4R antagonist to treat cachexia in patients with advanced cancers. For more information, visit www.kalohexis.com or follow us on LinkedIn and X. **Investor and Media Contact:** Argot Partners \[email protected\] SOURCE Kalohexis ### Related Stocks - [KLDO.US](https://longbridge.com/en/quote/KLDO.US.md) - [KLTO.US](https://longbridge.com/en/quote/KLTO.US.md) - [HALO.US](https://longbridge.com/en/quote/HALO.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [XHE.US](https://longbridge.com/en/quote/XHE.US.md) - [IHI.US](https://longbridge.com/en/quote/IHI.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) ## Related News & Research - [Marvell Now Sees as Much as $90 Billion in Annual Sales by Fiscal 2031. Here's Why It's a Chip Stock to Buy.](https://longbridge.com/en/news/301114413.md) - [Palantir vs. Oracle – Why Daniel Ives Says Buy One, Hold the Other](https://longbridge.com/en/news/301155464.md) - [Broadcom's AI Revenue Is Growing at 221%. Here's Why Custom Chips Could Be a Bigger Business Than GPUs.](https://longbridge.com/en/news/301141333.md) - [LIVE MARKETS-TSMC earnings could cause another round of consensus upgrades](https://longbridge.com/en/news/301145455.md) - [Marvell just impressed Wall Street with 'good numbers plus a better story'](https://longbridge.com/en/news/301066509.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**